Fall 2023: A Focus on Drug Testing and Cytogenetics

ARUP Pioneers New Approaches to Deliver Answers Patients Can Trust

Stories That Bring Laboratory Medicine to Life

Magnify Main Page

ARUP Continues to Pioneer Improved Drug Testing to Support Patient Care

ARUP’s Clinical Toxicology and Pharmacogenomics team members share a determination to drive change that leads to better patient outcomes and yields quality results for tens of thousands of patients each month.

Visionary Clinical Toxicologist Gwen McMillin Has Transformed Drug Testing to Better Support Clinical Needs

Colleagues describe Gwen McMillin, PhD, DABCC (CC, TC), FAACC, scientific director for the mass spectrometry platform and medical director of Clinical Toxicology at ARUP Laboratories, as someone who has a vast and intricate knowledge of everything related to clinical toxicology but who never loses sight of the goal of testing.

ARUP Takes a Forward-Thinking Approach to Newborn Drug Screening

A focus on quick, accurate, qualitative test results to inform time-sensitive decision-making keeps ARUP at the forefront of newborn drug screening.

Answers Patients Can Trust

As other labs have discontinued cytogenetics testing, ARUP has committed to this highly specialized testing for the long term, investing in instruments and space and continuing to build expertise with a goal to increase testing volumes by 20% a year.